In the latest trading session, 0.55 million Nuvation Bio Inc (NYSE:NUVB) shares changed hands as the company’s beta touched 1.13. With the company’s most recent per share price at $1.24 changed hands at -$0.11 or -8.15% at last look, the market valuation stands at $272.73M. NUVB’s current price is a discount, trading about -105.65% off its 52-week high of $2.55. The share price had its 52-week low at $0.95, which suggests the last value was 23.39% up since then. When we look at Nuvation Bio Inc’s average trading volume, we note the 10-day average is 0.99 million shares, with the 3-month average coming to 1.24 million.
Nuvation Bio Inc (NYSE:NUVB) trade information
Instantly NUVB was in red as seen in intraday trades today. With action -8.15%, the performance over the past five days has been red. The drop to weekly highs of 1.4100 on Monday, 11/20/23 subtracted -8.15% to the stock’s daily price. The company’s shares are showing year-to-date downside of -35.42%, with the 5-day performance at -8.15% in the red. However, in the 30-day time frame, Nuvation Bio Inc (NYSE:NUVB) is 7.83% up. Looking at the short shares, we see there were 2.4 million shares sold at short interest cover period of 1.64 days.
The consensus price target for the stock as assigned by Wall Street analysts is $3.73, meaning bulls need an upside of 66.76% from its recent market value. According to analyst projections, NUVB’s forecast low is $1.40 with $5.00 as the target high. To hit the forecast high, the stock’s price needs a -303.23% plunge from its current level, while the stock would need to soar -12.9% for it to hit the projected low.
Nuvation Bio Inc (NUVB) estimates and forecasts
Data shows that the Nuvation Bio Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -28.32% over the past 6 months, a 18.75% in annual growth rate that is considerably higher than the industry average of 14.80%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Nuvation Bio Inc will fall -10.00%.
The 2023 estimates are for Nuvation Bio Inc earnings to increase by 18.75%.
Nuvation Bio Inc is expected to release its next quarterly earnings report on November 02.
Nuvation Bio Inc (NYSE:NUVB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 26.90% of Nuvation Bio Inc shares while 63.20% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 86.45%. There are 63.20% institutions holding the Nuvation Bio Inc stock share, with FMR, LLC the top institutional holder. As of Jun 29, 2023, the company held 14.92% of the shares, roughly 32.67 million NUVB shares worth $58.81 million.
Omega Fund Management, Llc holds the second largest percentage of outstanding shares, with 6.88% or 15.07 million shares worth $27.13 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Aug 30, 2023 were Fidelity Contrafund Inc and Fidelity Growth Company Fund. With 8.68 million shares estimated at $14.24 million under it, the former controlled 3.96% of total outstanding shares. On the other hand, Fidelity Growth Company Fund held about 2.47% of the shares, roughly 5.42 million shares worth around $8.89 million.